Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tadalafil - Eli Lilly

Drug Profile

Tadalafil - Eli Lilly

Alternative Names: Adcirca; Cialis; GF 196960; IC 351; LY 450190; Zalutia

Latest Information Update: 09 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline; ICOS Corporation
  • Developer Eli Lilly and Company; Gilead Sciences; GlaxoSmithKline; ICOS Corporation; Northwestern University; United Therapeutics Corporation
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Indoles; Pyridones; Small molecules; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia; Erectile dysfunction; Pulmonary arterial hypertension
  • Phase III Duchenne muscular dystrophy
  • No development reported Raynaud's disease
  • Discontinued Angina pectoris; Female sexual dysfunction; Gastroparesis; Heart failure

Most Recent Events

  • 04 Apr 2019 Eli Lilly completes a phase I/II trial in Pulmonary arterial hypertension (In infants, In children, In adolescents) in USA, Canada, France, Poland, Spain and the United Kingdom (NCT01484431)
  • 20 Nov 2017 The US FDA grants paediatric exclusivity for Tadalafil tablets through May 21, 2018 for use in paediatric patients with Duchenne muscular dystrophy
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Raynaud's-disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top